NAD+ modulation of intestinal macrophages renders anti-inflammatory functionality and ameliorates gut inflammation
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- BIOMEDICINE & PHARMACOTHERAPY185 · 2025
- 피인용
- Scopus 13
- FWCI (Scopus)
- 3.56
- JCR IF
- JCR 2024 7.5
- ISSN
- 0753-3322
저자
- Kim, Young-In제1저자Laboratory of Microbiology, Department of Pharmacy, and Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou University, Suwon 16499, Republic of Korea
- 고인석Department of Chemistry Education, Graduate Department of Chemical Materials, Pusan National University, Busan, Republic of Korea
- Yi, Eun-JeLaboratory of Microbiology, Department of Pharmacy, and Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou University, Suwon 16499, Republic of Korea
- Kim, JusikLmito Therapeutics, Yongin-si 16827, Republic of Korea
- Hong, Yong RaeLmito Therapeutics, Yongin-si 16827, Republic of Korea
- Lee, WheeseongLmito Therapeutics, Yongin-si 16827, Republic of Korea
- Chang, Sun-Young교신저자Laboratory of Microbiology, Department of Pharmacy, and Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou University, Suwon 16499, Republic of Korea
초록
Macrophages can maintain gut immune homeostasis by driving clearance of infection, but also can prevent chronic inflammation and induce tissue repair. Reduced nicotinamide adenine dinucleotide (NAD+) levels in macrophages have been reported to be associated with the onset of severe colitis. Given that dysregulation of gut macrophages plays a significant role in inflammatory bowel disease (IBD), they represent a potential target for novel therapies. Here we show an IBD therapeutic candidate LMT503, a substrate that modulates NADH quinone oxidoreductase (NQO1), which induces anti-inflammatory macrophage polarization by NAD+ enhancement. To determine the anti-inflammatory effect of LMT503, a dextran sulfate sodium (DSS)-induced colitis mouse model was used in this study. Treatment of bone marrow-derived macrophages (BMDMs) with LMT503 increased IL-10 and Arg1 levels but decreased levels of TNF-α, iNOS, and IL-6. LMT503 also increased levels of SIRT1, SIRT3, and SIRT6, suggesting that macrophages were driven to an anti-inflammatory character. In a murine DSS-induced colitis model, oral treatment with LMT503 ameliorated colonic inflammation and decreased infiltrating monocytes and neutrophils. Although NAD+ enhancement did not alter CX3CR1intCD206- or CX3CR1hiCD206+ colon macrophage population, it decreased levels of TNF-α and iNOS and increased IL-10 level, with colonic macrophages showing an anti-inflammatory character shift. Depletion of CX3CR1 expressing gut resident macrophages abrogated the immune regulatory effect of LMT503 in the colon. These data suggest that LMT503 is a therapeutic candidate that can target macrophages to drive polarization with an immunosuppressive character and ameliorate IBD.
키워드
ColonGut macrophageInflammatory bowel diseaseMacrophage polarizationNAD+ modulation
식별자
- Scopus EID
- 2-s2.0-85218904866



로그인
연구물 목록으로